A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas

Omnitura Therapeutics

Status and phase

Completed

Phase 1

Conditions

Neoplasms

Treatments

Drug: Aneustat (OMN54)

Study type

Interventional

Funder types

Industry

Identifiers

NCT01555242

OMN54-101

Details and patient eligibility

About

This is a phase I, open-label, multiple dose, dose escalation study to assess the safety, tolerability and pharmacokinetics of Aneustat™ (OMN54), a novel therapy, administered orally in patients with advanced cancer and lymphomas.

Full description

Patients who complete a 28-day cycle, may be eligible to continue receiving Aneustat™ (OMN54) in 4-week increments for up to 6 cycles (inclusive of cycle 1) if further treatment is judged to be of possible benefit; if patient has not experienced unacceptable toxicity; and no study withdrawal criteria has been met.

Enrollment

22 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histological or cytological evidence of malignancy
Male or female, 18 years or older
Presence of advanced tumours, i.e., measurable or non-measurable disease (RECIST criteria, version 1.1)that have recurred or progressed following standard therapy
Able to swallow the oral capsule form of the drug
Failed at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
Haematology within 7 days of Day 1 (initial dose):
- Hemoglobin (Hb) > 9.0 g/dL
- Platelets ≥ 100,000 cells/mm3 (or, ≥100 x 10/L)
- Absolute neutrophil count (ANC) > 1.5 cells x109/L (or, > 1500 cells/mm3)
Chemistry within 7 days of Day 1 (initial dose):
- AST(SGOT)/ALT(SGPT) ≤ 2.5 x ULN if no liver metastases, AST(SGOT)/ALT(SGPT) < 5 x ULN if liver metastases
- Bilirubin < 1.5 x ULN unless Gilbert's Syndrome
- Serum creatinine ≤ 1.25 ULN
Coagulation within 7 days of Day 1 (initial dose):

*INR ≤ 1.5
ECOG Performance Status between 0 - 2 and estimated life expectancy of > 3 months.
Having the initiative and means to be compliant with the protocol (as judged by the Principal Investigator) and is within a feasible geographical proximity of the study center to make the required study visits.
Written informed consent obtained prior to any study screening procedures
Females of childbearing potential (a female is considered of childbearing potential unless she is postmenopausal, i.e., no menses for at least 12 consecutive months, or is without a uterus) must have a negative urine pregnancy test (UPT) within 7 days of Day 1 (initial dose)
Females of childbearing potential must agree to use an effective method of contraception (i.e., sexual abstinence, condoms, intrauterine device, diaphragm) from Screening period and throughout study participation.

Exclusion criteria

Patient has uncontrolled or symptomatic brain metastases (If a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days prior to Day 1 dosing).
Use of an investigational medication or device within 30 days of initiating study therapy (Day 1).
Major surgery within 30 days prior to first dose (Day 1).
Radiotherapy, chemotherapy, or immunotherapy within 28 days prior to Day 1 (not including palliative radiotherapy at focal sites).
Pregnancy or lactation.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (NY Heart Association Class III or IV, see Appendix 3), unstable angina pectoris, unstable cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements.
Screening (within approximately 28 days of registration) 12-lead electrocardiogram (ECG) that is abnormal and clinically significant
Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption.
Use of warfarin, i.e., Coumadin®, Jantoven® within 7 days prior to Day 1 (initial dosing)
Intolerance or aversion to porcine ingredients that are used for the OMN54 oral capsules in the investigational medicine, OMN54 (Aneustat™).
Known hypersensitivity to any of the three botanical constituents of Aneustat™ (OMN54), or other similar plants; or to plants belonging to Labiatae or Lamiaceae families, soy, or Aneustat™ (OMN54) excipients
Use of Sophora subprostrata root (SSR) or herba serissae within 14 days prior to Day 1.